comparemela.com

Latest Breaking News On - Abbvie genentech - Page 1 : comparemela.com

Venetoclax Monotherapy Leads to Durable Responses in Relapsed, Refractory CLL

The data showed notable responses, even among patients living with chronic lymphocytic leukemia (CLL) who had previous exposure to B-cell receptor–associated kinase inhibitors, the authors said.

Venetoclax venclextaPharmacyclics johnsonAbbvie genentechImage creditBrci pretreatedBcri naïveVenetoclax monotherapy

Ofatumumab, Methylprednisone, Lenalidomide Regimen Feasible as Frontline Therapy in CLL/SLL

Investigators reported the regimen had a tolerable safety profile, though they said its use may be limited due to the development of newer therapies.

Sebastian kaulitzkiAbbvie genentechEva sahakianH lee moffitt cancer centerResearch instituteClinical lymphomaMoffitt cancer center

Venetoclax Resistance in Patients With MDS Explained in New Study

The report offers new insights into the limits of the BCL2 inhibitor among patients who have myelodysplastic syndromes.

Abbvie genentechNature communications

Review Outlines Management of Patients Receiving Venetoclax for CLL

Risks like tumor lysis syndrome in the setting of chronic lymphocytic leukemia (CLL) require vigilant planning and coordination, authors say.

Venetoclax venclextaPharmacyclics janssenAbbvie genentechImage credit

Belantamab Mafodotin Plus Vd More Than Doubles PFS in Relapsed/Refractory Multiple Myeloma

Belantamab mafodotin plus bortezomib and dexamethasone improved PFS vs daratumumab plus bortezomib and dexamethasone in relapsed/refractory myeloma.

United statesRoche genentechRachid bazAbbvie genentechInternational staging systemMoffitt cancer centerRevised international staging systemBelantamab mafodotinMultiple myelomaPhase 3 dreamm 7 trial2024 february asco plenary seriesMaria victoria mateosHospital universitario de salamanca

vimarsana © 2020. All Rights Reserved.